Qt Imaging Holdings earnings release, August 12, 2026

Qt Imaging Holdings, Inc. (QTI) · Form 8-K, Item 2.02 · Filed · SEC filing

QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale

Second-quarter revenue reached $7.4 million; first-half revenue increased 116% to $14.0 million, with 28 scanners shipped

Strengthened capital position through a $10.0 million public offering and expanded direct U.S. commercial capabilities to accelerate adoption

Reaffirms full-year 2026 revenue guidance of approximately $39 million

Conference Call begins at 4:30 p.m. Eastern Time today

NOVATO, Calif., August 12, 2026 — QT Imaging Holding, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and six months ended June 30, 2026, and provided a business update.

“Our second quarter results demonstrate continued execution and the growing commercial momentum of QT Imaging. Revenue more than doubled year-over-year to $7.4 million, and we shipped fifteen Breast Acoustic CT scanners during the quarter, compared with eight in the prior-year period,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “We also took important steps to support continued growth, completing a $10 million public offering, expanding our direct U.S. sales organization, and securing regulatory authorization in Israel and Saudi Arabia. At the same time, we generated new evidence demonstrating less than 1% variability in Speed of Sound measurements across our scanners, successfully completed our first routine FDA inspection with zero Form 483 observations, and expanded manufacturing capacity through our new 22,000-square-foot facility. These are tangible steps toward scaling Breast Acoustic CT commercially while building the clinical, regulatory and operational foundation for broader adoption.”

“With more than 12,000 women already imaged using our technology, we are building more than an innovative medical imaging system; we are building a quantitative breast imaging platform that integrates advanced hardware, software, cloud infrastructure and, over time, AI-enabled clinical applications,” added Dr. Dinu. “At the same time, we continue to evolve our commercial strategy by complementing our established distribution partnerships with expanded direct commercial, and business development capabilities to accelerate customer engagement and broaden adoption. While geopolitical developments have impacted commercial activities in parts of the Gulf region, we are beginning to see encouraging signs of renewed customer engagement.”

Second Quarter and Recent Business Highlights

• Continued commercial execution:

QT Imaging shipped 15 Breast Acoustic CT scanners during the second quarter of 2026 and 28 scanners during the first six months of the year. The revenue for the second quarter of 2026 was $7.4 million. The Company continues to pursue commercial opportunities through a combination of established distribution partners and its expanding internal commercial and business development capabilities.

• Strengthened capital position:

During the second quarter, QT Imaging completed an underwritten public offering that generated approximately $10.0 million in gross proceeds. The Company also extended the maturity of its senior secured term loan by two years, from March 31, 2027, to March 31, 2029.

• Built a scalable U.S. commercial organization:

Under the leadership of our Chief Commercial Officer Satrajit Misra, a seasoned medical imaging executive with three decades of industry experience, QT Imaging expanded its direct commercial organization with the appointments of Jason Dyer as Vice President, Regional Sales East, and Dave Reinhart as Vice President, Regional Sales West. Together, this team strengthens the Company’s ability to directly engage breast imaging centers, clinicians and enterprise health systems, deepen strategic customer relationships and complement its established distribution partnerships, creating a scalable commercial model designed to accelerate adoption, grow the installed base and support long-term revenue growth and margin expansion.

• Expanded global regulatory foundation for Breast Acoustic CT scanners:

During the quarter, the Company received AMAR authorization from Israel’s Ministry of Health and Food and Drug Administration (“FDA”) regulatory clearance in Saudi Arabia. QT Imaging continues to pursue additional regulatory authorizations in the Gulf region and Europe.

• Successfully completed the Company’s first routine FDA inspection:

The inspection concluded with zero Form 483 observations, reflecting the strength of the Company’s Quality Management System and its focus on quality, compliance and manufacturing readiness.

• Generated additional scientific evidence:

A multi-site repeatability and reproducibility study demonstrated less than 1% variability in Speed of Sound measurements across Breast Acoustic CT scanners. The results support the potential use of objective and reproducible quantitative imaging biomarkers in longitudinal breast health assessment and treatment monitoring. These results reflect testing performed under the study conditions and do not represent a new FDA-cleared indication.

• Continued advancing the QTI technology platform:

Development activities included enhancements to image reconstruction, quantitative imaging algorithms, clinical workflow, and the QTI Precision Pathway™ cloud platform. The Company also continued its collaboration with Olea Medical to productize its multimodality image viewer, physician workflow and quantitative image analysis.

• Strengthened clinical and scientific leadership:... (truncated)tificial intelligence, with a proven track record of translating advanced technologies into clinically impactful products. Dr. Roseman brings more than 30 years of experience in breast cancer diagnosis, treatment and multidisciplinary patient care, providing deep clinical expertise to support physician engagement, clinical implementation, and broader adoption of our technology.

• Advanced clinical expansion in Israel:

Following our recent AMAR authorization from Israel’s Ministry of Health, the first Breast Acoustic CT scanner in Israel is planned for placement at

Rambam Health Care Campus, one of the country’s leading academic medical centers. The scanner will support a planned clinical study evaluating Breast Acoustic CT imaging modality in women with hereditary risk for breast cancer, expanding the Company’s clinical evidence-generation efforts in an important high-risk population.

• Expanded manufacturing capacity while improving operating efficiency:

Continued investing in manufacturing excellence and supply chain readiness while relocating to a new 22,000-square-foot headquarters and manufacturing facility, located in Petaluma, CA. The expanded facility provides more than 2.5x the operational space of the current location while reducing lease cost per square foot by approximately 55%, enhancing the Company's ability to scale production efficiently.

• Increased visibility within the investment community:

QT Imaging was added to the Russell Microcap® Index as part of the 2026 semi-annual Russell index reconstitution and following its return to the Nasdaq Capital Market in January.

• Pursued grassroots initiatives focused on breast health:

Dr. Dinu participated in two prestigious events hosted by The Shift, including its inaugural Shiftmakers Gala celebrating women driving change held at Harvard University and featuring actress and breast cancer survivor Olivia Munn, and presenting the Shiftmaker Award to tennis legend and two-time cancer survivor Martina Navratilova at the Sports Shiftmaker Awards ceremony during Wimbledon week in London.

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $7.4 million, an increase of 103% compared with $3.7 million for the second quarter of 2025. The increase was primarily attributable to the shipment of fifteen Breast Acoustic CT scanners in the 2026 quarter, compared with eight in the prior-year quarter.

Gross margin was 41% for the second quarter of 2026, compared with 50% for the second quarter of 2025. The gross margin for the second quarter of 2026 was in line with our projections for sales in the USA. The higher prior-year gross margin reflected a lower weighted average cost of inventory sold.

Total operating expenses were $4.9 million for the second quarter of 2026, compared with $2.9 million for the second quarter of 2025. The increase was primarily attributable to employee compensation and benefits, professional service costs, and marketing expenses.

Operating loss for the second quarter of 2026 was $1.9 million, compared with an operating loss of $1.0 million, for the second quarter of 2025 and $2.3 million for the first quarter of 2026.

Total interest and other expense, net, was $9.2 million during the second quarter of 2026, compared with $3.0 million in the prior-year quarter. The increase was due primarily to an $8.3 million non-cash loss on debt extinguishment related to the Lynrock Lake term loan modification.

Net loss for the second quarter of 2026 was $11.1 million, or $0.75 per share, compared with a net loss of $4.0 million, or $0.42 per share, for the second quarter of 2025. Prior-period share and per-share amounts have been adjusted to reflect the Company’s 3:1 reverse stock split completed in October 2025.

Non-GAAP adjusted EBITDA, which excludes interest, taxes, depreciation and amortization, other income or expense, changes in the fair value of financial liabilities, and stock-based compensation, was negative $1.2 million, or $0.08 per share, for the second quarter of 2026, compared with negative $0.8 million, or $0.08 per share, for the second quarter of 2025.

Net cash used in operating activities during the second quarter of 2026 was $4.8 million, compared with $1.4 million during the second quarter of 2025.

As of June 30, 2026, the Company had cash and restricted cash of $11.0 million, compared with $10.5 million as of December 31, 2025. As of August 7, 2026, the Company had cash and restricted cash of $14.2 million.

2026 Revenue Outlook

The Company affirms its 2026 revenue guidance of approximately $39 million. This outlook reflects minimum order quantities under its distribution agreements, as well as expected contributions from the Company’s direct sales efforts.

Conference Call and Webcast

QT Imaging management will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Participants are encouraged to pre-register here. Callers who are unable to pre-register can access the call by dialing 866-777-2509 (U.S.) or 412-317-5413 (international). A live and archived webcast of the call will be available at this link and on the

IR Calendar section of the QT Imaging website.

Non-GAAP Financial Measures... (truncated)ures should not be considered in isolation or as a substitute for the relevant GAAP measures and should be read in conjunction with information presented on a GAAP basis. Because not all companies use identical calculations, our presentation of non-GAAP measures may not be comparable to other similarly titled measures of other companies.

The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP and should not be considered measures of QT Imaging’s liquidity. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, many of the adjustments to our GAAP financial measures reflect the exclusion of certain items, as defined in our non-GAAP definitions below, which are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, even where similarly titled, limiting their usefulness for comparison purposes and therefore should not be used to compare QT Imaging’s performance to that of other companies. We endeavor to compensate for the limitation of the non-GAAP financial measures presented by also providing the most directly comparable GAAP measures and descriptions of the reconciling items and adjustments to derive the non-GAAP financial measures.

We believe these non-GAAP financial measures provide investors and analysts with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key measures used by management to operate and analyze our business over different periods of time.

EBITDA is defined as loss before interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for other expense (income), change in fair value of the warrant, derivative, and earnout liabilities, loss on issuance of debt, loss on debt extinguishment and modification, and stock-based compensation. Similar excluded expenses may be incurred in future periods when calculating these measures. QT Imaging believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. QT Imaging believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing QT Imaging’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors.

Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s consolidated financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which expense and income items are excluded or included in determining these non-GAAP financial measures.

Management uses EBITDA and Adjusted EBITDA as a non-GAAP performance measure that is defined in the accompanying tables and is reconciled to net loss, the most directly comparable GAAP measure, in the tables below.

We present reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures in the tables below.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems that use low-frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on

LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue7,4353,65913,9656,458
Cost of revenue4,3751,8328,2332,819
Gross profit3,0601,8275,7323,639
Operating expenses:Research and development1,6249013,3481,753
Operating expenses:Selling, general and administrative3,3001,9696,5973,971
Operating expenses:Total operating expenses4,9242,8709,9455,724
Operating expenses:Loss from operations-1,864-1,043-4,213-2,085
Interest and other expense, net:Interest expense, net-745-379-1,675-1,070
Interest and other expense, net:Other (expense) income, net-49-824
Interest and other expense, net:Change in fair value of warrant liability89-2,796-84-3,501
Interest and other expense, net:Change in fair value of derivative liability101
Interest and other expense, net:Change in fair value of earnout liability-250210-200160
Interest and other expense, net:Loss on issuance of debt-6,640
Interest and other expense, net:Loss on debt extinguishment and modification-8,294-8,294-2,124
Interest and other expense, net:Total interest and other expenses, net-9,204-2,956-10,261-13,050
Interest and other expense, net:Loss before income tax expense-11,068-3,999-14,474-15,135
Interest and other expense, net:Income tax expense2323
Interest and other expense, net:Net loss-11,070-4,002-14,476-15,138
Interest and other expense, net:Net loss attributable to common stockholders-11,070-4,002-14,476-15,138
Interest and other expense, net:Net loss per share - basic and diluted (1)-0.75-0.42-1.01-1.63
Interest and other expense, net:Weighted-average shares outstanding (1)14,8319,45114,3179,312

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net loss-11,070-4,002-14,476-15,138
Income tax expense2323
Interest expense, net7453791,6751,070
Depreciation and amortization21384176
EBITDA-10,302-3,582-12,758-13,989
Other expense (income), net4-98-24
Change in fair value of warrant liability (1)-892,796843,501
Change in fair value of derivative liability (2)-101
Change in fair value of earnout liability (3)250-210200-160
Loss on issuance of debt (4)6,640
Loss on debt extinguishment and modification (5)8,2948,2942,124
Stock-based compensation6682191,049320
Adjusted EBITDA-1,175-786-3,123-1,689

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026December 31, 2025
Cash and cash equivalents10,92410,412
Restricted cash and cash equivalents5050
Accounts receivable, net7,4045,781
Inventory9,8705,027
Prepaid expenses and other current assets1,171821
Total current assets29,41922,091
Property and equipment, net793318
Operating lease right-of-use assets, net379573
Other assets3939
Total assets30,63023,021
Current liabilities:Accounts payable3,0113,580
Current liabilities:Accrued expenses and other current liabilities6,0513,825
Current liabilities:Current maturities of long-term debt9
Current liabilities:Operating lease liabilities, current437454
Current liabilities:Total current liabilities9,4997,868
Current liabilities:Long-term debt11,397683
Current liabilities:Related party notes payable3,8953,895
Current liabilities:Operating lease liabilities203
Current liabilities:Warrant liability187103
Current liabilities:Earnout liability2,4102,210
Current liabilities:Other liabilities9961,614
Current liabilities:Total liabilities28,38416,576
Stockholders’ equity:Common stock11
Stockholders’ equity:Additional paid-in capital69,74559,468
Stockholders’ equity:Accumulated deficit-67,500-53,024
Stockholders’ equity:Total stockholders’ equity2,2466,445
Stockholders’ equity:Total liabilities and stockholders’ equity30,63023,021

Cash Flow

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net loss-14,476-15,138
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization4176
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation1,049320
Adjustments to reconcile net loss to net cash used in operating activities:Loss on issuance of debt6,640
Adjustments to reconcile net loss to net cash used in operating activities:Loss on debt extinguishment and modification8,2942,124
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest1,123548
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash operating lease-26-19
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value of warrant liability843,501
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value of derivative liability-101
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value of earnout liability200-160
Changes in operating assets and liabilities:Accounts receivable-1,623-3,584
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding QT Imaging’s quality and regulatory compliance and its ability to scale manufacturing, expand commercialization globally, and support a growing customer base, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT... (truncated)rd-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Investors

CORE IR

Tirth Patel ir@qtimaging.com

386-295-2215

Media

CORE IR

Matthew Cossel pr@qtimaging.com

212-655-0924

[Financial tables below]

Summary of Results

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

(1) Share and per share amounts for the three and six months ended June 30, 2025 differ from those published in prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split. Specifically, the number of shares of common stock outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 3:1, such that each three shares of common stock were combined and reconstituted into one share of common stock effective October 23, 2025.

EBITDA and Adjusted EBITDA

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

(1)

The change in fair value of warrant liability during the three and six months ended June 30, 2026 relates to the change in the market value of the private warrants outstanding as of June 30, 2026. The change in fair value of warrant liability during the three and six months ended June 30, 2025 relates to the change in the market value of the private placement warrants outstanding as of June 30, 2025, as well as the change in market value of the Lynrock Lake Warrant and Yorkville Warrant, which were revalued and reclassified to equity on June 11, 2025.

(2)

The change in fair value of derivative liability during the six months ended June 30, 2025 relates to the Yorkville Pre-paid Advance, which contained features that were bifurcated as freestanding financial instruments and initially valued on March 4, 2024 upon consummation of the Merger. The derivative liability was subsequently revalued as of February 26, 2025, prior to the extinguishment of the Yorkville Note.

(3)

The earnout liability relates to the contingent consideration for the Merger Earnout Consideration Shares pursuant to the Business Combination Agreement dated December 8, 2022, as amended in September 2023. The earnout liability was initially valued using the Monte Carlo Simulation method on March 4, 2024 and subsequently revalued using the same method as of June 30, 2026 and 2025.

(4)

Upon the issuance of the Lynrock Lake Term Loan, which closed on February 26, 2025, the Company recorded a loss of $6.6 million, including debt issuance costs of $0.2 million, during the six months ended June 30, 2025.

(5)... (truncated)uary 26, 2025.

Consolidated Balance Sheets

As of June 30, 2026 and December 31, 2025

(Unaudited)

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2026 and 2025

(Unaudited)

# # #

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Qt Imaging Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.